ClinPGx Blog (Page 21)

Sign in Subscribe

More issues

Curators' Favorite Papers

The first of two papers selected for the November edition of ”Curators' Favorite Papers" is from Nature Reviews Genetics (“Prioritizing diversity in human genomics research”). It highlights the necessity of including individuals from diverse backgrounds in genomic research, both as subjects and as researchers. The authors discuss several

CPIC Guideline Update: DPYD and Fluoropyrimidines

The 2017 update of the CPIC Guideline for Fluoropyrimidines and DPYD is now available as an advance online publication in Clinical Pharmacology and Therapeutics. CPIC extensively reviewed the literature up to March 2017. Both the dosing recommendations and supplemental information were updated. The accepted article can currently be viewed on

PharmVar Published in CPT

The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database has been published in the journal Clinical Pharmacology and Therapeutics. The paper describes the goals of the consortium and the database that will house pharmacogene variants and nomenclature. Visit the PharmVar website to learn more.

Study of Reimbursement of Preemptive Pharmacogenetic Testing by Health Insurance Payers

Researchers from the University of Mississippi School of Pharmacy and St. Jude Children’s Research Hospital have taken on one of the crucial barriers remaining in the movement of pharmacogenetic testing to the clinic--coverage and reimbursement of the preemptive pharmacogenetic testing by health insurance payers. The results appeared recently online

Curators' Favorite Papers

October’s edition of "Curators' Favorite Papers" features “Introducing personalized health for the family: the experience of a single hospital system”, a discussion about a preemptive pharmacogenomic (PGx) testing program in newborns at a Virginia hospital. The program, called MediMap Baby was initiated in 2014 with with

10 New Pharmacokinetics Pathways on PharmGKB

PharmGKB releases ten new PK pathways on the website: Antidepressants: Amitriptyline and Nortriptyline, Fluvoxamine, and BupropionAntipsychotics: Clozapine, Haloperidol and Olanzapine Antiepileptic: ClobazamNSAIs: NaproxenAnti-cancer drug: DasatinibAnti-hypertensive drug: Verapamil If you are interested in collaborating to develop these for publication as a PharmGKB summary in Pharmacogenetics and Genomics journal please email feedback@

Curators' Favorite Papers

For this month's edition of "Curators' Favorite Papers" we present two articles discussing how the recommendations from Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines have been used at two different healthcare settings. Implementation of Clinical Pharmacogenomics within a Large Health System: From Electronic Health Record Decision

Genotype-Guided Warfarin Dosing Lowers Rate of Composite Adverse Events vs. Clinical Dosing

Warfarin is a widely prescribed blood-thinning agent to prevent strokes, heart attacks, and blood blots. Despite the extensive literature documenting the significant association between CYP2C9/VKORC1 genotypes and warfarin dose, there's still debate surrounding the clinical utility of the genotype-guided warfarin dosing. A few large randomized clinical trials

PharmVar Launches Website

The Cytochrome P450 (CYP) Allele Nomenclature Database has transitioned to the Pharmacogene Variation Consortium at www.PharmVar.org. Please check out the PharmVar website!

Welcome to the new PharmGKB website!

We have just launched our new and improved user interface for PharmGKB! The new website offers benefits such as a display that works on mobile and small screen devices, improved searching and filtering capabilities and faster page load speeds. While the look of PharmGKB has changed, all the content that